Evidence map›Paper›PMID 39523323›Full record

ArticleBMC cancer2024

The impact of curative cancer treatment on sexual health - clinical results from the EORTC QLQ-SH22 validation study.

Anne S Oberguggenberger, Veronika I Engele, Claudia Schmalz, Andy Nordin, Vesna Bjelic-Radisic, Anne Lanceley, Karin Kuljanic, Pernille T Jensen, Ligita Paskeviciute Frøding, Carien L Creutzberg and 7 more

Abstract readValidation Study
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Anne S Oberguggenberger *Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, University Hospital of Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria. Anne.oberguggenberger@i-med.ac.at.
Veronika I Engele *Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, University Hospital of Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria.
Claudia SchmalzDepartment of Radiotherapy, University Hospital Schleswig-Holstein, Campus Kiel, Germany.
Andy NordinEast Kent Gynaecological Oncology Centre, Queen Elizabeth the Queen Mother Hospital, Margate, UK.
Vesna Bjelic-RadisicBreast Unit, Department of Obstetrics and Gynecology, Helios University Hospital Wuppertal, University Witten/Herdecke; Medical University of Graz, Graz, Austria.
Anne LanceleyUCL Elizabeth Garrett Anderson Institute for Women's Health, Dept Women's Cancer, University College London, London, UK.
Karin KuljanicClinical Unversity Hospital Centre Rijeka, Rijeka, Croatia.
Pernille T JensenDepartment of Gynaecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark.
Ligita Paskeviciute FrødingDepartment of Gynecology, Copenhagen University Hospital, Copenhagen, Denmark.
Carien L CreutzbergDepartment of Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands.
Kristin ZimmermannDepartment of Urology, Federal Armed Services Hospital Koblenz, Koblenz, Germany.
Samantha SerpentiniUnit of Psycho-Oncology/Breast Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
Juan I ArrarasComplejo Hospitalario de Navarra, Pamplona, Spain.
Eva NageleDepartment of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria.
Hilde ToelenUniversity Hospitals Leuven, UZ Campus Gasthuisberg, Leuven, Belgium.
Elfriede GreimelDepartment of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria.
EORTC Quality of Life Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe European Organization of Research and Treatment of Cancer (EORTC) has recently developed and validated a patient-reported outcome measure (PROM) for sexual health (SH) in cancer patients. Here, we present results from a secondary analysis of the EORTC QLQ-SH22 validation study. The objective was to investigate the impact of cancer treatment on SH over the disease trajectory into survivorship in patients who underwent curative treatment.

methodsParticipants completed the EORTC QLQ-SH22 and the EORTC QLQ-C30 assessing SH and Quality of Life. We analyzed differences in SH of patients on active cancer treatment compared to patients off-treatment (cross sectional group comparison) as well as changes in SH during the course of treatment (from pre-treatment to follow-up).

resultsOur sample consisted of n = 394 (66.2% females) curatively treated cancer patients with 34% of patients being on-treatment and 66% of patients being in their follow-up after primary treatment (off-treatment group). Compared to patients off- treatment, patients on active cancer treatment experienced less sexual satisfaction (p = .021, Cohen's d = .36) and libido (p < .001, d = .60) and had higher levels of fatigue (p < .001, d = .50). Importance of sexual activity, masculinity and femininity did not differ between groups. Treatment effects on sexual activity decreased with treatment completion (p < .001, d = .50). Patients undergoing intensified treatment (chemotherapy, radiation, or endocrine treatment) reported more treatment effects (subscale EORTC QLQ-SH22) compared to patients undergoing surgery only.

conclusionOur results highlight the negative impact of oncological treatment on SH and how increasing treatment intensity further impair SH. Sexual satisfaction and libido improve after treatment completion while other aspects (e.g. masculinity/femininity) do not change during survivorship. We suggest monitoring of SH from the start of cancer treatment on and beyond into survivorship using PROMs as part of routine cancer care. Routine monitoring allows systematic identification of patient's SH problems and may improve awareness as well as target intervention for those in need of care.

Indexed as

NeoplasmsPatient Reported Outcome MeasuresQuality of LifeSexual HealthAdultAgedCancer SurvivorsCross-Sectional StudiesFemaleHumansLibidoMaleMiddle AgedSexual BehaviorSurveys and QuestionnairesCancerEORTC QLGQuality of LifeSexual health

Identifiers

PMID39523323
PMCPMC11552421

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.